Global Anticoagulants Market

Global Anticoagulants Market Size, Share, Growth Analysis, By Drug class(Vitamin K Antagonists (VKAs) and Direct Oral Anticoagulants (DOACs)), By Distribution channel(Hospital Pharmacies, Retail Pharmacies) - Industry Forecast 2024-2031


Report ID: SQMIG35B2093 | Region: Global | Published Date: March, 2024
Pages: 219 | Tables: 61 | Figures: 75

Global Anticoagulants Market Insights

The Global Anticoagulants Market size size was valued at USD 28.50 Billion in 2022 and is poised to grow from USD 31.44 Billion in 2023 to USD 68.87 Billion by 2031, at a CAGR of 10.30% during the forecast period (2024-2031). 

Global anticoagulants market has witnessed significant growth in recent years, driven by rising prevalence of chronic diseases and the adoption of unhealthy lifestyles that have contributed to the growing incidence of cardiovascular diseases. Consequently, there is a rising demand for anticoagulants in the market. According to the World Health Organization (WHO) and the Cureus Journal of Medical Science, cardiovascular diseases are a leading cause of death worldwide, with approximately 17.9 million deaths occurring annually, representing 35% of global deaths. Among these deaths, 85% are attributed to heart attacks and strokes. Ischemic heart disease (IHD) has emerged as a prominent contributor to global mortality. It affects around 126 million individuals worldwide, accounting for approximately 1.72% of the world's population. Moreover, projections indicate that the prevalence of IHD is expected to surpass 1,845 per 100,000 individuals by 2030. Anticoagulants help prevent blood clotting, reducing the risk of heart attacks, strokes, and other cardiovascular complications. In addition to conventional anticoagulant therapies, novel oral anticoagulants (NOACs) have gained prominence. These newer drugs offer advantages such as improved safety profiles, simplified dosing regimens, and fewer drug interactions compared to traditional anticoagulants like warfarin. The growing adoption of NOACs by healthcare professionals and patients has further fueled the growth of the global anticoagulants market.

US Anticoagulants Market is poised to grow at sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

The Global Anticoagulants Market size size was valued at USD 28.50 Billion in 2022 and is poised to grow from USD 31.44 Billion in 2023 to USD 68.87 Billion by 2031, at a CAGR of 10.30% during the forecast period (2024-2031). 

The global anticoagulants market is characterized by a diverse range of pharmaceutical companies and research institutions striving to develop innovative anticoagulant therapies. These players focus on research and development activities to introduce novel treatment options with improved efficacy and safety profiles. Collaborations and partnerships are also common strategies to enhance product portfolios and expand market reach. Additionally, regulatory approvals and clinical trials play a crucial role in shaping the competitive dynamics of the market, as they determine the commercial success of new anticoagulant drugs. 'Pfizer Inc. (US)', 'Bayer AG (Germany)', 'Bristol Myers Squibb Company (US)', 'Johnson & Johnson (US)', 'Boehringer Ingelheim International GmbH (Germany)', 'Sanofi S.A. (France)', 'Daiichi Sankyo Company, Limited (Japan)', 'Novartis International AG (Switzerland)', 'Eli Lilly and Company (US)', 'AstraZeneca PLC (UK)', 'Merck & Co., Inc. (US)', 'GlaxoSmithKline PLC (UK)', 'Abbott Laboratories (US)', 'Aspen Pharmacare Holdings Limited (South Africa)', 'Otsuka Holdings Co., Ltd. (Japan)', 'Mylan N.V. (US)', 'Takeda Pharmaceutical Company Limited (Japan)', 'Leo Pharma A/S (Denmark)', 'Portola Pharmaceuticals, Inc. (US)', 'CSL Limited (Australia)'

One key driver of the global anticoagulants market is the increasing prevalence of cardiovascular diseases, including ischemic heart disease (IHD), worldwide. With millions of deaths each year attributed to cardiovascular diseases, there is a growing need for effective treatments to prevent heart attacks and strokes. This rising disease burden has resulted in a higher demand for anticoagulant medications, driving the growth of the market. Additionally, the adoption of novel oral anticoagulants (NOACs) has further fueled the market expansion, offering improved safety and convenience compared to traditional anticoagulants.

One key trend in the global anticoagulants market is the increasing adoption of direct oral anticoagulants (DOACs) over traditional anticoagulant therapies such as warfarin. DOACs offer advantages such as predictable dosing, fewer drug interactions, and reduced need for frequent monitoring compared to warfarin. The shift towards DOACs is driven by the convenience and improved safety profiles they offer, leading to better patient adherence. Additionally, ongoing research and development efforts are focused on expanding the range of indications for DOACs, further driving their popularity in the market.

North America holds a significant share in the global anticoagulants market. The region's dominance can be attributed to several factors, including a high prevalence of cardiovascular diseases, a well-established healthcare infrastructure, and the presence of key market players. The United States, in particular, plays a crucial role in driving the growth of the anticoagulants market in North America, owing to its large population and advanced healthcare system.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Anticoagulants Market

Product ID: SQMIG35B2093

$5,300
BUY NOW GET FREE SAMPLE